The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma
Open accessAbstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • It had been hypothesized that there must be a relationship between free IgE concentrations and the signs and symptoms of asthma – after all, this is what drove the development of omalizumab. • However, although many statistical analyses of free IgE and spirometry data for patients equilibrated on omalizumab had shown a difference between placebo and treatment, no consistent time‐ and IgE‐dependent relationship had been shown due to the narrow range of free IgE being studied and the sparse nature of the sampling and clinical measurements in Phase III trials. WHAT THIS STUDY ADDS • The above problem was solved using a pharmacokinetic–pharmacodynamic (PK–PD) model to estimate free IgE concentrations for all time points throughout and after treatment with omalizumab, together with patient daily diary data. • This allowed for the first time the direct correlation between free IgE and signs and symptoms of asthma to be observed. • Doses and regimens for omalizumab could then be derived, through PK–PD model simulation, for suppressing free IgE to a point correlated with an improvement in clinical symptoms. AIMS: Omalizumab, a subcutaneously administered anti‐IgE antibody, is effective for moderate‐to‐severe persistent allergic asthma. The aims were to (i) describe the population pharmacodynamics of free IgE with a mechanism‐based, nonlinear, omalizumab–IgE binding model; (ii) deduce a target‐free IgE suppression level by correlation with clinical outcomes; and (iii) check the adequacy of current approved dosing tables and explore potential doses and regimens beyond. METHODS: Concentration data (omalizumab, free and total IgE) were obtained from 1781 patients aged 12–79 years, in four sparsely sampled randomized, placebo‐controlled studies and 152 subjects in a richly sampled single‐dose study. NONMEM predictive performance across the range of bodyweights (39–150 kg) and baseline IgE (19–1055 IU ml−1) was checked by simulation. Predicted free IgE levels were correlated with time‐averaged patient diary clinical outcomes. RESULTS: The model accurately predicted observed omalizumab, free and total IgE concentrations. Free IgE concentrations correlated well with clinical signs and symptoms, allowing a target concentration of 14 ng ml−1, at the midpoint of 4‐week clinical observation periods, to be set for determining the dose and regimen for omalizumab. CONCLUSIONS: The omalizumab–IgE binding model is predictive for free IgE and demonstrates a nonlinear time‐dependent relationship between free IgE suppression and clinical outcomes in asthma. Although currently approved dosing tables are close to optimal, it should be possible to treat patients with higher levels of baseline IgE if higher doses can be administered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A General Model for the Origin of Allometric Scaling Laws in Biology
West, G. B., Brown, J. H., & Enquist, B. J. (1997) · Science · doi:10.1126/science.276.5309.122 · Cited by 5,016
The Fourth Dimension of Life: Fractal Geometry and Allometric Scaling of Organisms
West, G. B., Brown, J. H., & Enquist, B. J. (1999) · Science · doi:10.1126/science.284.5420.1677 · Cited by 1,718
Cited by
Type 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
Lee, J. W., Kelley, M., King, L. E., Yang, J., Salimi-Moosavi, H., Tang, M. T., Lu, J.-F., Kamerud, J., Ahene, A., Myler, H., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9251-3 · Cited by 270
Omalizumab and mast cell disorders: are we there yet?
Weiler, C. R. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.04.030 · Cited by 9
Metadata
- Authors
- Lowe, P. J., Tannenbaum, S., Gautier, A., & Jimenez, P.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-07
- Volume
- 68
- Issue
- 1
- Pages
- 61-76
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2164367822
- Cited by
- 168
- References
- 2
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma. https://app.cochat.ai/papers/10.1111/j.1365-2125.2009.03401.x
- The paper
- Lowe, P. J., Tannenbaum, S., Gautier, A., & Jimenez, P. (2009). Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2009.03401.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.